Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CLK1 | P49759 | 4/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564274 | 0.94 | KDM4E (0.58) | TBXAS1KDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL7336540 | 0.83 | TBXAS1 (0.57) | TBXAS1 | |
| SCHEMBL18893480 | 0.83 | KDM4E (0.58) | TBXAS1KDM4EALDH1A1PDGFRBPDGFRA | |
| SCHEMBL5564937 | 0.83 | TBXAS1 (0.59) | TBXAS1CLK1DYRK1ADYRK1BCLK2 | |
| SCHEMBL5566031 | 0.82 | TBXAS1 (0.54) | TBXAS1KDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL5559819 | 0.82 | TBXAS1 (0.61) | TBXAS1CLK1DYRK1ADYRK1BCLK2 | |
| SCHEMBL5764549 | 0.81 | TBXAS1 (0.56) | TBXAS1KDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL5565054 | 0.80 | TBXAS1 (0.56) | TBXAS1KDM4ECLK1DYRK1ADYRK1B | |
| SCHEMBL18893482 | 0.79 | HPGD (0.51) | TBXAS1KDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL26109906 | 0.77 | TBXAS1 (0.58) | TBXAS1KDM4EALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208491-B2 | N-monoacylated o-phenylenediamines | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| EP-1594857-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | claimed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | claimed |
| US-7208491-B2 | N-monoacylated o-phenylenediamines | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1594857-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HDAC1, HDAC11, HDAC7 | TBXAS1 3283/4885KDM4E 137/4885ALDH1A1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.